On the stock market since 2013, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 52% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 36% a year on average.
Sales run at $152.9M a year. A small number, but proof the product has real buyers.
A loss of $143.5M against $152.9M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, FMI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: FMI is a high-risk stock — not yet profitable, and its future rides on its product catching on.